Arnold C Hanish
CIK 1233253 · Chief Accounting Officer · last filed 2026-09-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LLY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SEATTLE, WA 98119
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DCOY | Director | 3,418 | $0.99 | $3.4K | $0 | 1 | 2026-09-02 |
| OMER | Director | 17,400 | $16.59 | $288.7K | -$303.2K | 19 | 2026-08-28 |
| Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Director | 5,000 | $0.84 | $4.2K | $65.2K | 18 | 2026-01-02 |
| LLY | Chief Accounting Officer | 26,201 | $1268.68 | $33.24M | -$375.5K | 14 | 2012-10-30 |
Recent Filings · Page 4 of 6
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-02-12 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Buy (P) | +3,000 | $10.8K | EDGAR |
| 2019-11-26 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Buy (P) | +3,000 | $10.8K | EDGAR |
| 2019-09-12 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-11 | OMER | Grant (A) | — | $0 | EDGAR |
| 2018-06-18 | OMER | Grant (A) | — | $0 | EDGAR |
| 2017-06-16 | OMER | Grant (A) | — | $0 | EDGAR |
| 2016-06-10 | OMER | Grant (A) | — | $0 | EDGAR |
| 2015-05-27 | OMER | Grant (A) | — | $0 | EDGAR |
| 2013-05-28 | OMER | Grant (A) | — | $0 | EDGAR |
| 2013-01-03 | OMER | Buy (P) | +2,000 | $11.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.